Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition
Life expectancy is increasing and so is the prevalence of age-related non-communicable diseases (NCDs). Consequently, older people and patients present with multi-morbidities and more complex needs, putting significant pressure on healthcare systems. Effective nutrition interventions could be an imp...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/12/9/2555 |
id |
doaj-d3c6d2dc96ef4fafb3666178b4556102 |
---|---|
record_format |
Article |
spelling |
doaj-d3c6d2dc96ef4fafb3666178b45561022020-11-25T03:40:08ZengMDPI AGNutrients2072-66432020-08-01122555255510.3390/nu12092555Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical NutritionBarbara Troesch0Manfred Eggersdorfer1Alessandro Laviano2Yves Rolland3A. David Smith4Ines Warnke5Arved Weimann6Philip C. Calder7Nutrition Science and Advocacy, DSM Nutritional Products, 4303 Kaiseraugst, SwitzerlandDepartment of Internal Medicine, University Medical Center Groningen, 9713 GZ Groningen, The NetherlandsDepartment of Translational and Precision Medicine, Sapienza University, 00185 Rome, ItalyGérontopôle de Toulouse, Institut du Vieillissement, INSERM 1027, Centre Hospitalo-Universitaire de Toulouse, 31300 Toulouse, FranceDepartment of Pharmacology, University of Oxford, Oxford OX1 2JD, UKNutrition Science and Advocacy, DSM Nutritional Products, 4303 Kaiseraugst, SwitzerlandClinic for General, Visceral and Oncological Surgery, St. Georg gGmbH Clinic, 04129 Leipzig, GermanyFaculty of Medicine, University of Southampton and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton SO16 6YD, UKLife expectancy is increasing and so is the prevalence of age-related non-communicable diseases (NCDs). Consequently, older people and patients present with multi-morbidities and more complex needs, putting significant pressure on healthcare systems. Effective nutrition interventions could be an important tool to address patient needs, improve clinical outcomes and reduce healthcare costs. Inflammation plays a central role in NCDs, so targeting it is relevant to disease prevention and treatment. The long-chain omega-3 polyunsaturated fatty acids (omega-3 LCPUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are known to reduce inflammation and promote its resolution, suggesting a beneficial role in various therapeutic areas. An expert group reviewed the data on omega-3 LCPUFAs in specific patient populations and medical conditions. Evidence for benefits in cognitive health, age- and disease-related decline in muscle mass, cancer treatment, surgical patients and critical illness was identified. Use of DHA and EPA in some conditions is already included in some relevant guidelines. However, it is important to note that data on the effects of omega-3 LCPUFAs are still inconsistent in many areas (e.g., cognitive decline) due to a range of factors that vary amongst the trials performed to date; these factors include dose, timing and duration; baseline omega-3 LCPUFA status; and intake of other nutrients. Well-designed intervention studies are required to optimize the effects of DHA and EPA in specific patient populations and to develop more personalized strategies for their use.https://www.mdpi.com/2072-6643/12/9/2555clinical nutritionoral nutritional supplementationDHA and EPAlong-chain omega-3 polyunsaturated fatty acidsinflammationAlzheimer’s disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Barbara Troesch Manfred Eggersdorfer Alessandro Laviano Yves Rolland A. David Smith Ines Warnke Arved Weimann Philip C. Calder |
spellingShingle |
Barbara Troesch Manfred Eggersdorfer Alessandro Laviano Yves Rolland A. David Smith Ines Warnke Arved Weimann Philip C. Calder Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition Nutrients clinical nutrition oral nutritional supplementation DHA and EPA long-chain omega-3 polyunsaturated fatty acids inflammation Alzheimer’s disease |
author_facet |
Barbara Troesch Manfred Eggersdorfer Alessandro Laviano Yves Rolland A. David Smith Ines Warnke Arved Weimann Philip C. Calder |
author_sort |
Barbara Troesch |
title |
Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition |
title_short |
Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition |
title_full |
Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition |
title_fullStr |
Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition |
title_full_unstemmed |
Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition |
title_sort |
expert opinion on benefits of long-chain omega-3 fatty acids (dha and epa) in aging and clinical nutrition |
publisher |
MDPI AG |
series |
Nutrients |
issn |
2072-6643 |
publishDate |
2020-08-01 |
description |
Life expectancy is increasing and so is the prevalence of age-related non-communicable diseases (NCDs). Consequently, older people and patients present with multi-morbidities and more complex needs, putting significant pressure on healthcare systems. Effective nutrition interventions could be an important tool to address patient needs, improve clinical outcomes and reduce healthcare costs. Inflammation plays a central role in NCDs, so targeting it is relevant to disease prevention and treatment. The long-chain omega-3 polyunsaturated fatty acids (omega-3 LCPUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are known to reduce inflammation and promote its resolution, suggesting a beneficial role in various therapeutic areas. An expert group reviewed the data on omega-3 LCPUFAs in specific patient populations and medical conditions. Evidence for benefits in cognitive health, age- and disease-related decline in muscle mass, cancer treatment, surgical patients and critical illness was identified. Use of DHA and EPA in some conditions is already included in some relevant guidelines. However, it is important to note that data on the effects of omega-3 LCPUFAs are still inconsistent in many areas (e.g., cognitive decline) due to a range of factors that vary amongst the trials performed to date; these factors include dose, timing and duration; baseline omega-3 LCPUFA status; and intake of other nutrients. Well-designed intervention studies are required to optimize the effects of DHA and EPA in specific patient populations and to develop more personalized strategies for their use. |
topic |
clinical nutrition oral nutritional supplementation DHA and EPA long-chain omega-3 polyunsaturated fatty acids inflammation Alzheimer’s disease |
url |
https://www.mdpi.com/2072-6643/12/9/2555 |
work_keys_str_mv |
AT barbaratroesch expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition AT manfredeggersdorfer expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition AT alessandrolaviano expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition AT yvesrolland expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition AT adavidsmith expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition AT ineswarnke expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition AT arvedweimann expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition AT philipccalder expertopiniononbenefitsoflongchainomega3fattyacidsdhaandepainagingandclinicalnutrition |
_version_ |
1724536115961004032 |